Monique J. Roobol
Erasmus University Medical Center
CancerInternal medicineRadiologyUrologyOncologyRandomized controlled trialBiopsyProstate cancer screeningProstateDiseaseOverdiagnosisProstatectomyRectal examinationProstate cancerProstate biopsyProstate-specific antigenPopulationGynecologyMass screeningMedicineCohort
613Publications
76H-index
11.4kCitations
Publications 623
Newest
#1H.B. LuitingH-Index: 4
#2Antti RannikkoH-Index: 30
Last. Monique J. RoobolH-Index: 76
view all 9 authors...
Source
Source
Source
Source
Source
#2André DeschampsH-Index: 1
Last. Monique J. RoobolH-Index: 76
view all 7 authors...
Source
Source
#1Alex Qinyang Liu (CUHK: The Chinese University of Hong Kong)
#2Sebastiaan Remmers (EUR: Erasmus University Rotterdam)H-Index: 6
Last. Monique J. Roobol (EUR: Erasmus University Rotterdam)H-Index: 76
view all 12 authors...
BACKGROUND Men with elevated prostate-specific antigen (PSA) and initial negative prostate biopsy may have risk of prostate cancer (PCa) in the future. The role of Prostate Health Index (phi) in determining future PCa risk has not been studied before. This study aims to investigate the role of initial phi and phi density in predicting future PCa risk in men with initial negative biopsy. METHODS Five hundred sixty nine men with PSA 4-10 ng/mL were recruited between 2008 and 2015 for prostate biop...
Source
#1Hendrik Van Poppel (Katholieke Universiteit Leuven)H-Index: 82
#2Monique J. Roobol (EUR: Erasmus University Rotterdam)H-Index: 76
Last. Manfred P. Wirth (TUD: Dresden University of Technology)H-Index: 65
view all 8 authors...
Abstract null null Background null Recommendations against prostate-specific antigen (PSA) testing in 2012 have increased advanced-stage diagnosis and prostate cancer–specific mortality rates. null null null Objective null To present the position of the European Association of Urology (EAU) in 2021 and provide recommendations for the use of PSA testing as part of a risk-adapted strategy for the early detection of prostate cancer. null null null Evidence acquisition null The authors combined thei...
Source
#1Paul Doan (Westmead Hospital)H-Index: 1
#2Petra L. Graham (Macquarie University)H-Index: 23
Last. Manish I. Patel (USYD: University of Sydney)H-Index: 27
view all 7 authors...
OBJECTIVE To externally validate and compare the performance of the European Randomized Study of Screening for Prostate Cancer risk calculator 3/4 (ERSPC-RC3/4), the Prostate Biopsy Collaborative Group risk calculator (PBCG-RC) and the van Leeuwen model to determine which prediction model would perform the best in a contemporary Australian cohort undergoing transperineal (TP) biopsy. MATERIALS AND METHODS A retrospective review identified all patients undergoing TP biopsy across two centres. Of ...
Source